Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome
European Journal of Gastroenterology and Hepatology, ISSN: 0954-691X, Vol: 17, Issue: 1, Page: 21-26
2005
- 45Citations
- 73Captures
- 2Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations45
- Citation Indexes45
- 45
- CrossRef38
- Captures73
- Readers73
- 73
- Mentions2
- References2
- Wikipedia2
Review Description
Many patients with irritable bowel syndrome (IBS) are disillusioned by the lack of efficacy of treatments and suffer from numerous symptoms not covered by the Rome criteria for IBS, as the current empirical treatment regimens fail to address these persistent debilitating 'IBS associated symptoms'. These symptoms are similar to other symptom complexes like chronic fatigue and the so-called 'candida syndrome', and many seek help from alternative medicine. The possible role of Candida and yeasts in non-immune compromised individuals is disputed and is the subject of this review. Even if the involvement of yeasts in the aetiology of IBS still remains unclear, there is increasing evidence for yeasts being able to cause IBS-symptoms in sensitized patients via Candida products, antigens and cross-antigens. But more research is needed before antifungal treatment can be recommended as a first line treatment for IBS. © 2005 Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=12344274361&origin=inward; http://dx.doi.org/10.1097/00042737-200501000-00005; http://www.ncbi.nlm.nih.gov/pubmed/15647635; http://journals.lww.com/00042737-200501000-00005; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00042737-200501000-00005; http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=XPjGHhzjq6GCRbwP5kb3127bJ9jFhZ5QSBcPWwFkcqPtqZJrTrjY!-1552860756!181195628!8091!-1?sid=WKPTLP:landingpage&an=00042737-200501000-00005
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know